Protein carbonyl groups as biomarkers of oxidative stress

被引:1760
作者
Dalle-Donne, I
Rossi, R
Giustarini, D
Milzani, A
Colombo, R
机构
[1] Univ Milan, Dept Biol, I-20133 Milan, Italy
[2] Univ Siena, Dept Neurosci, I-53100 Siena, Italy
关键词
reactive oxygen species; 2,4-dinitrophenylhydrazine; carbonyl assay; human diseases; oxyblot;
D O I
10.1016/S0009-8981(03)00003-2
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Oxidative stress, an imbalance toward the pro-oxidant side of the pro-oxidant/antioxidant homeostasis, occurs in several human diseases. Among these diseases are those in which high levels of protein carbonyl (CO) groups have been observed, including Alzheimer's disease (AD), rheumatoid arthritis, diabetes, sepsis, chronic renal failure, and respiratory distress syndrome. What relationships might be among high level of protein CO groups, oxidative stress, and diseases remain uncertain. The usage of protein CO groups as biomarkers of oxidative stress has some advantages in comparison with the measurement of other oxidation products because of the relative early formation and the relative stability of carbonylated proteins. Most of the assays for detection of protein CO groups involve derivatisation of the carbonyl group with 2,4-dinitrophenylhydrazine (DNPH), which leads to formation of a stable dinitrophenyl (DNP) hydrazone product. This then can be detected by various means, such as spectrophotometric assay, enzyme-linked immunosorbent assay (ELISA), and one-dimensional or two-dimensional electrophoresis followed by Western blot immunoassay. At present, the measurement of protein CO groups after their derivatisation with DNPH is the most widely utilized measure of protein oxidation. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:23 / 38
页数:16
相关论文
共 111 条
  • [1] Proteolysis in severe sepsis is related to oxidation of plasma protein
    Abu-Zidan, FM
    Plank, LD
    Windsor, JA
    [J]. EUROPEAN JOURNAL OF SURGERY, 2002, 168 (02) : 119 - 123
  • [2] Differential oxidative damage to mitochondrial proteins during aging
    Agarwal, S
    Sohal, RS
    [J]. MECHANISMS OF AGEING AND DEVELOPMENT, 1995, 85 (01) : 55 - 63
  • [3] Oxidative modification of creatine kinase BB in Alzheimer's disease brain
    Aksenov, M
    Aksenova, M
    Butterfield, DA
    Markesbery, WR
    [J]. JOURNAL OF NEUROCHEMISTRY, 2000, 74 (06) : 2520 - 2527
  • [4] Protein oxidation in the brain in Alzheimer's disease
    Aksenov, MY
    Aksenova, MV
    Butterfield, DA
    Geddes, JW
    Markesbery, WR
    [J]. NEUROSCIENCE, 2001, 103 (02) : 373 - 383
  • [5] Oxidative protein damage in human diabetic eye: Evidence of a retinal participation
    Altomare, E
    Grattagliano, I
    Vendemaile, G
    MicelliFerrari, T
    Signorile, A
    Cardia, L
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1997, 27 (02) : 141 - 147
  • [6] Oxidative stress is found in amyloid deposits in systemic amyloidosis
    Ando, Y
    Nyhlin, N
    Suhr, O
    Holmgren, G
    Uchida, K
    ElSahly, M
    Yamashita, T
    Terasaki, H
    Nakamura, M
    Uchino, M
    Ando, M
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 232 (02) : 497 - 502
  • [7] Carbonylation and disassembly of the F-actin cytoskeleton in oxidant induced barrier dysfunction and its prevention by epidermal growth factor and transforming growth factor α in a human colonic cell line
    Banan, A
    Zhang, Y
    Losurdo, J
    Keshavarzian, A
    [J]. GUT, 2000, 46 (06) : 830 - 837
  • [8] iNOS upregulation mediates oxidant-induced disruption of F-actin and barrier of intestinal monolayers
    Banan, A
    Fields, JZ
    Zhang, Y
    Keshavarzian, A
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2001, 280 (06): : G1234 - G1246
  • [9] OPC-compounds prevent oxidant-induced carbonylation and depolymerization of the F-actin cytoskeleton and intestinal barrier hyperpermeability
    Banan, A
    Fitzpatrick, L
    Zhang, Y
    Keshavarzian, A
    [J]. FREE RADICAL BIOLOGY AND MEDICINE, 2001, 30 (03) : 287 - 298
  • [10] Banan A, 1999, J PHARMACOL EXP THER, V291, P1075